Hansa Biopharma announces positive reimbursement decision in Spain for Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation
Lund, Sweden, March 29, 2023. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that the Spanish Minister of Health (Ministerio de Sanidad) has granted access and reimbursement to Idefirix[®], the company’s first-in-class treatment, for the desensitization of highly sensitized adult patients prior to kidney transplant from a deceased donor. The positive reimbursement decision follows the conditional approval granted by EMA in August 2020.[1] Søren Tulstrup, President and CEO, Hansa Biopharma said, “At